236 related articles for article (PubMed ID: 37586764)
1. PPARγ activation modulates the balance of peritoneal macrophage populations to suppress ovarian tumor growth and tumor-induced immunosuppression.
Prat M; Coulson K; Blot C; Jacquemin G; Romano M; Renoud ML; AlaEddine M; Le Naour A; Authier H; Rahabi MC; Benmoussa K; Salon M; Parny M; Delord JP; Ferron G; Lefèvre L; Couderc B; Coste A
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586764
[TBL] [Abstract][Full Text] [Related]
2. Identification of a tissue-specific, C/EBPβ-dependent pathway of differentiation for murine peritoneal macrophages.
Cain DW; O'Koren EG; Kan MJ; Womble M; Sempowski GD; Hopper K; Gunn MD; Kelsoe G
J Immunol; 2013 Nov; 191(9):4665-75. PubMed ID: 24078688
[TBL] [Abstract][Full Text] [Related]
3. Defining and targeting tumor-associated macrophages in malignant mesothelioma.
Wu L; Kohno M; Murakami J; Zia A; Allen J; Yun H; Chan M; Baciu C; Liu M; Serre-Beinier V; De Palma M; Felley-Bosco E; Yeung J; Pugh TJ; de Perrot M
Proc Natl Acad Sci U S A; 2023 Feb; 120(9):e2210836120. PubMed ID: 36821580
[TBL] [Abstract][Full Text] [Related]
4. Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer.
Wilson AJ; Saskowski J; Barham W; Khabele D; Yull F
Mol Cancer; 2015 Nov; 14():192. PubMed ID: 26552746
[TBL] [Abstract][Full Text] [Related]
5. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
6. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.
Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
Front Immunol; 2019; 10():1273. PubMed ID: 31214202
[TBL] [Abstract][Full Text] [Related]
7. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the immune landscapes of advanced ovarian cancer in an optimized in vivo model.
Pisano S; Lenna S; Healey GD; Izardi F; Meeks L; Jimenez YS; Velazquez OS; Gonzalez D; Conlan RS; Corradetti B
Clin Transl Med; 2021 Oct; 11(10):e551. PubMed ID: 34709744
[TBL] [Abstract][Full Text] [Related]
9. Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer.
Glass EB; Hoover AA; Bullock KK; Madden MZ; Reinfeld BI; Harris W; Parker D; Hufnagel DH; Crispens MA; Khabele D; Rathmell WK; Rathmell JC; Wilson AJ; Giorgio TD; Yull FE
BMC Cancer; 2022 May; 22(1):497. PubMed ID: 35513776
[TBL] [Abstract][Full Text] [Related]
10. VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients.
Khan ANH; Emmons TR; Magner WJ; Alqassim E; Singel KL; Ricciuti J; Eng KH; Odunsi K; Tomasi TB; Lee K; Abrams SI; Mesa C; Segal BH
Cancer Immunol Immunother; 2022 Oct; 71(10):2355-2369. PubMed ID: 35166871
[TBL] [Abstract][Full Text] [Related]
11. Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
Yoshida M; Taguchi A; Kawana K; Adachi K; Kawata A; Ogishima J; Nakamura H; Fujimoto A; Sato M; Inoue T; Nishida H; Furuya H; Tomio K; Arimoto T; Koga K; Wada-Hiraike O; Oda K; Nagamatsu T; Kiyono T; Osuga Y; Fujii T
PLoS One; 2016; 11(8):e0160330. PubMed ID: 27483433
[TBL] [Abstract][Full Text] [Related]
12. Role of M2-like macrophages in the progression of ovarian cancer.
Baek SH; Lee HW; Gangadaran P; Oh JM; Zhu L; Rajendran RL; Lee J; Ahn BC
Exp Cell Res; 2020 Oct; 395(2):112211. PubMed ID: 32755554
[TBL] [Abstract][Full Text] [Related]
13. Adipocyte‑rich microenvironment promotes chemoresistance via upregulation of peroxisome proliferator‑activated receptor gamma/ABCG2 in epithelial ovarian cancer.
Chen S; Liu Z; Wu H; Wang B; Ouyang Y; Liu J; Zheng X; Zhang H; Li X; Feng X; Li Y; Shen Y; Zhang H; Xiao B; Yu C; Deng W
Int J Mol Med; 2024 Apr; 53(4):. PubMed ID: 38426604
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
Zhu X; Xu J; Cai H; Lang J
J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
[TBL] [Abstract][Full Text] [Related]
15. Protein arginine methyltransferase 1 modulates innate immune responses through regulation of peroxisome proliferator-activated receptor γ-dependent macrophage differentiation.
Tikhanovich I; Zhao J; Olson J; Adams A; Taylor R; Bridges B; Marshall L; Roberts B; Weinman SA
J Biol Chem; 2017 Apr; 292(17):6882-6894. PubMed ID: 28330868
[TBL] [Abstract][Full Text] [Related]
16. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
[TBL] [Abstract][Full Text] [Related]
17. Activation of peroxisome proliferator-activated receptor-γ by a 12/15-lipoxygenase product of arachidonic acid: a possible neuroprotective effect in the brain after experimental intracerebral hemorrhage.
Xu R; Wang S; Li W; Liu Z; Tang J; Tang X
J Neurosurg; 2017 Sep; 127(3):522-531. PubMed ID: 27739938
[TBL] [Abstract][Full Text] [Related]
18. Effects of macrophage-dependent peroxisome proliferator-activated receptor γ signalling on adhesion formation after abdominal surgery in an experimental model.
Hong GS; Schwandt T; Stein K; Schneiker B; Kummer MP; Heneka MT; Kitamura K; Kalff JC; Wehner S
Br J Surg; 2015 Nov; 102(12):1506-16. PubMed ID: 26313905
[TBL] [Abstract][Full Text] [Related]
19. Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment.
Alexander ET; Minton AR; Peters MC; van Ryn J; Gilmour SK
Oncotarget; 2016 Dec; 7(51):85291-85305. PubMed ID: 27852034
[TBL] [Abstract][Full Text] [Related]
20. The Activin A-Peroxisome Proliferator-Activated Receptor Gamma Axis Contributes to the Transcriptome of GM-CSF-Conditioned Human Macrophages.
Nieto C; Bragado R; Municio C; Sierra-Filardi E; Alonso B; Escribese MM; Domínguez-Andrés J; Ardavín C; Castrillo A; Vega MA; Puig-Kröger A; Corbí AL
Front Immunol; 2018; 9():31. PubMed ID: 29434585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
